Market
How much will Zepbound affect Eli Lilly's stock price by end of 2025?
2
Resolution / Starting Odds
Stock price increases by less than 5% • 25%
Stock price increases by 5% to 10% • 25%
Stock price increases by 10% to 15% • 25%
Stock price increases by more than 15% • 25%
Stock market data and financial analysis reports
Story
Medicare to Cover Eli Lilly's Zepbound for Sleep Apnea Following FDA Approval
Jan 8, 2025, 08:34 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent FDA approval, making Zepbound the first medication specifically approved for moderate-to-severe OSA. The coverage under Medicare Part D is expected to enhance the drug's market potential, as it is already recognized as a significant treatment option for obesity-related conditions.
View original story
Similar markets
No • 50%
Yes • 50%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
$1 billion to $2 billion • 25%
Less than $1 billion • 25%
Yes • 50%
No • 50%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
No • 50%
Yes • 50%
5 or more new partnerships • 25%
3-4 new partnerships • 25%
1-2 new partnerships • 25%
0 new partnerships • 25%
Yes • 50%
No • 50%
500,000 to 1 million • 25%
Less than 500,000 • 25%
1 million to 2 million • 25%
More than 2 million • 25%